Related Experiment Videos
Visual function loss from vigabatrin: effect of stopping the drug
M A Johnson1, G L Krauss, N R Miller
1Maryland Center for Eye Care, University of Maryland, Baltimore, USA.
Neurology
|July 13, 2000
Summary
Visual function loss from vigabatrin (an antiepileptic drug) is generally not reversible after discontinuation. While some mild improvements in visual acuity and color vision may occur, significant visual field deficits typically persist.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Vigabatrin is an effective antiepileptic medication.
- It is known to cause visual dysfunction, including visual field reduction, decreased visual acuity, impaired color vision, and abnormal electroretinogram (ERG) and electro-oculogram (EOG) findings.
- The reversibility of these visual changes after discontinuing vigabatrin is not well-established.
Purpose of the Study:
- To investigate whether visual function deficits associated with vigabatrin use improve after the medication is stopped.
- To assess the reversibility of specific visual parameters affected by vigabatrin.
Main Methods:
- Evaluated visual fields (static and kinetic), visual acuity, color vision, and ERG in patients on vigabatrin.
- Re-assessed these parameters in 13 patients after discontinuing vigabatrin due to lack of efficacy or visual field reduction.
- Follow-up ranged from 3 months to nearly 1 year off the drug.
Main Results:
- Most patients did not experience improvement in clinical visual function measures (visual acuity, color vision, visual fields) or ERG amplitudes.
- ERG cone implicit time showed improvement in some patients.
- A subset of patients with minimal visual field loss on vigabatrin demonstrated substantial recovery of ERG amplitudes.
- Multifocal ERG indicated diffuse, non-peripheral visual function loss.
Conclusions:
- Visual field loss due to vigabatrin is generally irreversible.
- Most patients do not recover visual function after stopping vigabatrin.
- Visual acuity, color vision, and ERG amplitude loss may be reversible in patients with minimal or no visual field impairment.